Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Prolanta||Prolanta is a prolactin-based peptide containing a G129R mutation that acts as an antagonist of the prolactin receptor, leading to increased autophagy and cell death, and potentially resulting in decreased tumor growth (PMID: 24703838).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02534922||Phase I||Prolanta||Study of Prolanta in Recurrent or Persistent Epithelial Ovarian Cancer (ProlantaOC)||Unknown status||USA||0|